According to endocrinologists, the muscle loss during GLP-1 or semaglutide medication use is not unique to the drug its a consequence commonly seen in caloric restriction
Timeline based on Highland Longevity patient data and SURMOUNT clinical trial outcomes
Fatigue during the initial weeks is mentioned by some users as the appetite suppression takes effect and caloric intake drops, the body adjusts to running on less fuel
1,2 Glucagon binds to a G protein-coupled receptor mostly found in the liver but also in the kidney, adrenal gland, gut, and pancreas
This suggests that microbial and metabolic disruptions become increasingly entrenched over time, highlighting the urgent need for early, targeted interventions using specialized prebiotic fibers to halt the progression of dysbiosis and restore SCFA production before permanent neurological damage occurs